Psoriatic Arthritis

Knowledge is power. Are you facing a new diagnosis or recurrence of Psoriatic Arthritis? The Spine Community Psoriatic Arthritis Information Center has current, evidence-based information for you. Get the facts about the prevention, treatment, and living with Psoriatic Arthritis. Stay up to date with news, tips, and features designed to keep you informed about the most recent developments and advances. Learn more about Psoriatic Arthritis.

The Spine Community Psoriatic Arthritis Community & Discussions

You are not alone—The Spine Community is the leading Social Media Application for individuals seeking information, inspiration, and support for back pain and conditions of the spine. The network offers patients and caregivers a thriving community for support and information. Login or register here.

PSORIATIC ARTHRITIS NEWS TIPS & FEATURES

How To Enjoy The Holidays Despite Chronic Pain

December 20th, 2016

How To Enjoy The Holidays Despite Chronic Pain

By Tom Macek, M.D. The holidays are a time when everyone is encouraged to be of good cheer. But this joyous time of year is a lot less merry for those suffering from chronic bad backs, migraines, arthritis and other pain-inducing ailments. “Any kind of pain can seriously affect your quality of life,” says Dr. […]


Cosentyx® Improves Pain and Function in Patients with Psoriatic Arthritis

September 22nd, 2016

Cosentyx® Improves Pain and Function in Patients with Psoriatic Arthritis

By David Borenstein MD, Executive Editor, theSpineCommunity.com In January of 2016, the Food and Drug Administration approved Cosentyx® (secukinumab) for the treatment of psoriatic arthritis (PsA) and ankylosing spondylitis. Psoriatic spondylitis, an inflammatory spine disease, is a component of PsA responsive to Cosentyx therapy. The availability of Cosentyx allows another option for PsA patients with spine […]


FDA Arthritis Advisory Committee Recommends Approval of Adalimumab Biosimilar

August 23rd, 2016

FDA Arthritis Advisory Committee Recommends Approval of Adalimumab Biosimilar

The Food and Drug Administration’s Arthritis Advisory Committee recommended that Amgen biosimilar (ABP 501) to Humira (adalimumab) be approved for use in the United States. The panel unanimously voted, 26-0, that ABP 501 be recommended for use in the same indications as adalimumab: rheumatoid arthritis (RA), juvenile idiopathic, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, adult Crohn’s disease, […]


Long-Term Safety of Humira® Reported in Analyses of over 15,000 Patients

August 9th, 2016

Long-Term Safety of Humira® Reported in Analyses of over 15,000 Patients

A review of the long-term outcomes and safety issues associated with the TNF inhibitor, Humira® (adalimumab) was recently published. Humira works by blocking the inflammatory effects of a protein called tumor necrosis factor alpha (TNF alpha) in rheumatoid arthritis (RA) and other conditions associated with inflammation. The body produces TNF when there is inflammation and […]


What is EULAR and Why You Should Care

June 7th, 2016

What is EULAR and Why You Should Care

By David Borenstein MD, Executive Editor, theSpineCommunity.com What is EULAR? EULAR is an acronym for the European Union League Against Rheumatism. It is the second largest professional rheumatologic organization. The annual meeting for this organization is taking place next week in London, England, where more than a thousand presentations and abstracts will be presented about back […]


Strength Train at Home

April 29th, 2016

Strength Train at Home

Maintaining muscle strength through regular exercise as we age can help combat natural muscle loss, or sarcopenia. By Joan Pagano Sarco-What? Sarcopenia is the natural loss of muscle strength and function that occurs with aging. If you are over 40, you are already experiencing creeping muscle loss. Is it reversible? Yes—but only with an appropriate […]


More News →

CONDITIONS OF THE GI TRACT